Join
Live feed
·
PRReleasevia Quantisnow
Unity Biotechnology Inc. logo

UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
UBX· Unity Biotechnology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track UBX (Unity Biotechnology Inc.) and more on Quantisnow.